The ABPI and NC3Rs report, 'From models to medicines', examines the development of human-relevant pre-clinical models in the UK, with an emphasis on academic pre-commercial models and their transfer to industry for drug and vaccine development.[1][2] It revealed a significant gap in translational readiness between predictive models developed in universities and the needs of pharmaceutical companies.[1][2] About 10 percent of drug research and development programs eventually lead to an approved drug, with the lack of predictive methods in the preclinical phase a major technical barrier to drug discovery.[2] The UK has a strong but fragmented pre-clinical model environment with good infrastructure investment and technical strengths but gaps.[1] In 2024, ABPI proposed the establishment of a center for translational models where academics and industry would collaborate to develop and scale up in vitro models.[1][2] The Government's Plan for Life Sciences includes a commitment to the creation of such a centre, with an initial focus on liver, lung, heart and gut organoids.[1][2] The report highlights the need for more targeted investment and education to better translate models into industry and reduce animal use.[2]